Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Quoin Pharmaceuticals Ltd QNRX

Healthcare Biotechnology
Quoin Pharmaceuticals Ltd, former Cellect Biotechnology Ltd, is an Israel-based specialty pharmaceutical company, focused on developing and commercializing therapeutic products that treat rare and orphan diseases. The Company’s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology... see more

Recent & Breaking News (NDAQ:QNRX)

Quoin Pharmaceuticals Signs Exclusive Distribution Agreement with Orpharm LLC for its Lead Asset, QRX003, for Netherton Syndrome

GlobeNewswire December 15, 2021

The R&D Sweet Spot: Quoin Pharmaceuticals Delivering Value-Based Drug Development Through Rare and Orphan Disease Therapeutics

Newsfile December 14, 2021

Quoin Pharmaceuticals Poised for Rapid Commercialization of Promising Pipeline

Newsfile November 16, 2021

Quoin Pharmaceuticals and Genpharm Services Sign Exclusive License and Distribution Agreement for Quoin's Lead Asset, QRX003

GlobeNewswire November 11, 2021

Quoin Pharmaceuticals Signs Exclusive Licensing and Distribution Agreement with AFT Pharmaceuticals for its Lead Asset, QRX003

GlobeNewswire November 8, 2021

Quoin Pharmaceuticals Appoints Gordon Dunn as Chief Financial Officer 

GlobeNewswire November 4, 2021

Quoin Pharmaceuticals Announces Signing of Exclusive License from Queensland University of Technology, Australia

GlobeNewswire November 2, 2021

Cellect Biotechnology Announces Record Date and Distribution Date for CVRs in Connection with Strategic Merger with Quoin Pharmaceuticals

GlobeNewswire October 15, 2021

Cellect Biotechnology Announces Shareholder Approval of Strategic Merger with Quoin Pharmaceuticals

GlobeNewswire September 27, 2021

Cellect Biotechnology Announces the ApoGraft(TM) Bone Marrow Transplantation of First Patient in U.S.

GlobeNewswire September 2, 2021

Cellect Biotechnology Reports Second Quarter 2021 Financial and Operating Results

GlobeNewswire August 24, 2021

The Securities and Exchange Commission Declared Cellect Biotechnology's Registration Statement Filed on Form F-4 Effective in Connection with its Previously Announced Strategic Merger with Quoin Pharmaceuticals

GlobeNewswire August 13, 2021

Cellect Biotechnology Files Registration Statement in Connection with Proposed Strategic Merger Agreement with Quoin Pharmaceuticals

GlobeNewswire June 16, 2021

Cellect Biotechnology Reports Top Line Data from Phase 1/2 Clinical Trial

GlobeNewswire April 19, 2021

Cellect Biotechnology Reports Fourth Quarter and Full Year 2020 Financial and Operating Results

GlobeNewswire March 29, 2021

Cellect Biotechnology and Quoin Pharmaceuticals Announce Strategic Merger

GlobeNewswire March 24, 2021

Cellect Biotechnology Reports Third Quarter Financial and Operating Results; Recent Developments Position Company to Accelerate Progress in 2021

GlobeNewswire November 20, 2020

Cellect Biotechnology Commences Collaboration with XNK Therapeutics to Advance Novel NK Cell-Based Therapies; Adds Another Partner for its Functional Cell Selection Technology

GlobeNewswire October 29, 2020

Cellect Biotechnology Initiates U.S. Clinical Trial of ApoGraft

GlobeNewswire October 22, 2020

Cellect Biotechnology to Present at the 2020 Cell & Gene Meeting on the Mesa

GlobeNewswire September 21, 2020